vs
Side-by-side financial comparison of Laird Superfood, Inc. (LSF) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
Entrada Therapeutics, Inc. is the larger business by last-quarter revenue ($20.6M vs $13.3M, roughly 1.5× Laird Superfood, Inc.). Laird Superfood, Inc. runs the higher net margin — -13.2% vs -84.4%, a 71.2% gap on every dollar of revenue. On growth, Laird Superfood, Inc. posted the faster year-over-year revenue change (15.0% vs -65.2%). Over the past eight quarters, Laird Superfood, Inc.'s revenue compounded faster (16.1% CAGR vs 6.4%).
Laird Superfood, Inc. develops, manufactures and sells a portfolio of plant-based functional superfood products, including premium coffee creamers, hydration blends, nutritional supplements, and plant-powered snacks. It serves health-conscious consumers through direct-to-consumer e-commerce platforms and offline retail partners, mainly operating in the North American market with a focus on sustainably sourced clean ingredients.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
LSF vs TRDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $13.3M | $20.6M |
| Net Profit | $-1.8M | $-17.3M |
| Gross Margin | 34.1% | — |
| Operating Margin | -13.5% | -106.0% |
| Net Margin | -13.2% | -84.4% |
| Revenue YoY | 15.0% | -65.2% |
| Net Profit YoY | -341.4% | -173.8% |
| EPS (diluted) | — | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.3M | — | ||
| Q3 25 | $12.9M | — | ||
| Q2 25 | $12.0M | — | ||
| Q1 25 | $11.7M | $20.6M | ||
| Q4 24 | $11.6M | $37.4M | ||
| Q3 24 | $11.8M | $19.6M | ||
| Q2 24 | $10.0M | $94.7M | ||
| Q1 24 | $9.9M | $59.1M |
| Q4 25 | $-1.8M | — | ||
| Q3 25 | $-975.1K | — | ||
| Q2 25 | $-362.2K | — | ||
| Q1 25 | $-156.2K | $-17.3M | ||
| Q4 24 | $-398.4K | $1.1M | ||
| Q3 24 | $-166.1K | $-14.0M | ||
| Q2 24 | $-239.1K | $55.0M | ||
| Q1 24 | $-1.0M | $23.5M |
| Q4 25 | 34.1% | — | ||
| Q3 25 | 36.5% | — | ||
| Q2 25 | 39.9% | — | ||
| Q1 25 | 41.9% | — | ||
| Q4 24 | 38.6% | — | ||
| Q3 24 | 43.0% | — | ||
| Q2 24 | 41.8% | — | ||
| Q1 24 | 40.0% | — |
| Q4 25 | -13.5% | — | ||
| Q3 25 | -7.7% | — | ||
| Q2 25 | -3.3% | — | ||
| Q1 25 | -1.9% | -106.0% | ||
| Q4 24 | -4.1% | -15.7% | ||
| Q3 24 | -2.3% | -110.7% | ||
| Q2 24 | -3.4% | 56.4% | ||
| Q1 24 | -11.0% | 35.7% |
| Q4 25 | -13.2% | — | ||
| Q3 25 | -7.6% | — | ||
| Q2 25 | -3.0% | — | ||
| Q1 25 | -1.3% | -84.4% | ||
| Q4 24 | -3.4% | 3.0% | ||
| Q3 24 | -1.4% | -71.7% | ||
| Q2 24 | -2.4% | 58.1% | ||
| Q1 24 | -10.3% | 39.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-0.42 | ||
| Q4 24 | — | $-0.20 | ||
| Q3 24 | — | $-0.35 | ||
| Q2 24 | — | $1.55 | ||
| Q1 24 | — | $0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.1M | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $11.5M | $417.3M |
| Total Assets | $19.2M | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.1M | — | ||
| Q3 25 | $5.1M | — | ||
| Q2 25 | $3.9M | — | ||
| Q1 25 | $7.0M | $67.8M | ||
| Q4 24 | $8.3M | $101.2M | ||
| Q3 24 | $7.9M | $78.0M | ||
| Q2 24 | $7.6M | $185.3M | ||
| Q1 24 | $7.1M | $68.4M |
| Q4 25 | $11.5M | — | ||
| Q3 25 | $12.8M | — | ||
| Q2 25 | $13.4M | — | ||
| Q1 25 | $13.3M | $417.3M | ||
| Q4 24 | $13.2M | $428.7M | ||
| Q3 24 | $13.1M | $422.4M | ||
| Q2 24 | $12.6M | $429.9M | ||
| Q1 24 | $12.7M | $269.4M |
| Q4 25 | $19.2M | — | ||
| Q3 25 | $18.9M | — | ||
| Q2 25 | $20.4M | — | ||
| Q1 25 | $21.5M | $486.5M | ||
| Q4 24 | $19.3M | $526.3M | ||
| Q3 24 | $18.8M | $554.6M | ||
| Q2 24 | $18.0M | $582.0M | ||
| Q1 24 | $17.6M | $510.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $68.4K | $-38.5M |
| Free Cash FlowOCF − Capex | — | $-39.7M |
| FCF MarginFCF / Revenue | — | -192.9% |
| Capex IntensityCapex / Revenue | — | 5.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $68.4K | — | ||
| Q3 25 | $1.2M | — | ||
| Q2 25 | $-2.8M | — | ||
| Q1 25 | $-1.3M | $-38.5M | ||
| Q4 24 | $339.2K | $-31.6M | ||
| Q3 24 | $305.8K | $-24.3M | ||
| Q2 24 | $642.7K | $39.8M | ||
| Q1 24 | $-422.3K | $-25.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-39.7M | ||
| Q4 24 | — | $-32.2M | ||
| Q3 24 | — | $-24.9M | ||
| Q2 24 | — | $38.8M | ||
| Q1 24 | — | $-26.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -192.9% | ||
| Q4 24 | — | -86.2% | ||
| Q3 24 | — | -127.3% | ||
| Q2 24 | — | 41.0% | ||
| Q1 24 | — | -44.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.6% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -27.94× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.72× | ||
| Q1 24 | — | -1.09× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LSF
| Wholesale | $7.0M | 52% |
| Coffee Tea And Hot Chocolate Products | $4.4M | 33% |
| Hydration And Beverage Enhancing Supplements | $1.6M | 12% |
| Other | $352.6K | 3% |
TRDA
Segment breakdown not available.
